🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🎉 Thrilled to present TWO posters today at ASCO #GI25 🗓️ Poster 1: Utilization of circulating tumor DNA (ctDNA) testing in biliary tract cancers. (E20) 🗓️ Poster 2: Safety and efficacy of anti-HER2 agents in the treatment of biliary tract cancers: A systematic review. (E15)

Thanks to everyone who stopped by my posters at ASCO GI! I appreciated the discussions on the use of #ctDNA in BTCs. Looking forward to connecting again soon! #GI25 Dr Amit Mahipal Sakti Chakrabarti, MD Case Western/UH IM Chiefs

Nikolas Naleid, MD, PharmD Biomedicines MDPI Sakti Chakrabarti, MD Dr Amit Mahipal We would like to inform you that your post has been published on @Oncodaily. Thank you for sharing! oncodaily.com/science/nikola…

Excited to share our systematic review on pembrolizumab safety in GI cancers - Nikolas Naleid, MD, PharmD oncodaily.com/url/231244 Sakti Chakrabarti, MD Dr Amit Mahipal Biomedicines MDPI #Cancer #GIOnc #GI25 #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

Watch as Dr Amit Mahipal delves into the complex case of a 57-year-old woman diagnosed with advanced unresectable #HCC. #HepatocellularCarcinoma #PatientCare | Case Comp Cancer Ctr hubs.li/Q039fZNH0

Credit to JCO Oncology Practice for publishing this study - ascopubs.org/doi/full/10.12… Small, single institution experience but likely informative of our collective experience -<50% of pts completed all planned CapeOX cycles -~30% experience grade III or greater AEs -~18% hospitalized

Patient centered #GIonc study by Sakti Chakrabarti, MD feat Nikolas Naleid, MD, PharmD Real world 🌎study N=153 with adj 💉 #crcsm <50% completed all #CAPOX - ⬇️ rates for ♀️ ⬆️ #tox 🖐️🦶⚡️🔥 More #pallonc needed ASCO PallOnc Community of Practice 🔗: ascopubs.org/doi/full/10.12… OncoAlert🚨 #OncoAlertAF Emre Yekedüz

Thrilled to share our new publication! Anti-HER2 therapies show promise in HER2+ BTCs with 34% response rate & 64% disease control. Pooled analysis (n=368) supports their use, esp. 2nd-line. Toxicity manageable. Dr Amit Mahipal Sakti Chakrabarti, MD Ankit Mangla, MD ascopubs.org/doi/10.1200/PO…

Great job, Nikolas Naleid, MD, PharmD. Rising star under the amazing mentorship of Dr Amit Mahipal University Hospitals Case Western Reserve Case Comp Cancer Ctr

💊Anti-HER2 agents in biliary tract cancers JCO Precision Oncology ✅ORR:34% (95% CI, 24 to 44) ✅DCR:64% (95% CI, 51 to 77) ✅mPFS: 4.8 mo ✅mOS: 9.4 mo 🚨G3-4 AE: 32.1% 👉doi.org/10.1200/PO-24-… ASCO OncoAlert #cancer #oncology #MedX Cholangiocarcinoma Foundation Precision-BTC-Network